RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsIndeed a tough yr for Mersana & their PH1 ADC cancer trial. It's out of the FDA hold, but shares have plummeted 75% & they've halved their staff. This PH1 biotech has a MC of $143m, even after a truly disastrous yr. PH3 Oncy, $113m MC...Wake up Coffey.